These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 7219332

  • 1. [What role does secondary hyperaldosteronism play in decompensated liver cirrhosis?].
    Albert JP, Hartmann F.
    Med Klin; 1981 Jan 30; 76(3):74-7. PubMed ID: 7219332
    [Abstract] [Full Text] [Related]

  • 2. [Secondary hyperaldosteronism in patients with liver cirrhosis, frequently caused by therapy].
    Spech HJ.
    Fortschr Med; 1979 Apr 19; 97(15):714-8. PubMed ID: 456975
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Serum levels of magnesium in hepatic cirrhosis].
    Pasqualetti P, Casale R, Colantonio D, Di Lauro G, Festuccia V, Natali L, Natali G.
    Quad Sclavo Diagn; 1987 Mar 19; 23(1):12-7. PubMed ID: 3441590
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Sodium retention in heart failure and cirrhosis: potential role of natriuretic doses of mineralocorticoid antagonist?
    Bansal S, Lindenfeld J, Schrier RW.
    Circ Heart Fail; 2009 Jul 19; 2(4):370-6. PubMed ID: 19808361
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Hyponatremia of cirrhosis: role of vasopressin and decreased 'effective' plasma volume.
    Akriviadis EA, Ervin MG, Cominelli F, Fisher DA, Reynolds TB.
    Scand J Gastroenterol; 1997 Aug 19; 32(8):829-34. PubMed ID: 9282977
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Significances of plasma levels of neuropeptide Y pre- and post-treatment in patients with decompensated cirrhosis and ascites].
    Li GW, Wu LD, Zhu Y.
    Di Yi Jun Yi Da Xue Xue Bao; 2003 May 19; 23(5):483-4. PubMed ID: 12754138
    [Abstract] [Full Text] [Related]

  • 12. Ratio of serum aldosterone to plasma renin concentration in essential hypertension and primary aldosteronism.
    Trenkel S, Seifarth C, Schobel H, Hahn EG, Hensen J.
    Exp Clin Endocrinol Diabetes; 2002 Apr 19; 110(2):80-5. PubMed ID: 11928071
    [Abstract] [Full Text] [Related]

  • 13. Components of the renin-angiotensin-aldosterone system in plasma and ascites in hepatic cirrhosis.
    Kuiper JJ, Boomsma F, van Buren H, de Man R, Danser AH, van den Meiracker AH.
    Eur J Clin Invest; 2008 Dec 19; 38(12):939-44. PubMed ID: 19021719
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Renal effects of treatment with diuretics, octreotide or both, in non-azotemic cirrhotic patients with ascites.
    Kalambokis G, Economou M, Fotopoulos A, Bokharhii JA, Katsaraki A, Tsianos EV.
    Nephrol Dial Transplant; 2005 Aug 19; 20(8):1623-9. PubMed ID: 15886218
    [Abstract] [Full Text] [Related]

  • 18. Refractory ascites in cirrhosis: roles of volume expansion and plasma atrial natriuretic factor level elevation.
    Wong F, Tobe S, Legault L, Logan AG, Skorecki K, Blendis LM.
    Hepatology; 1993 Sep 19; 18(3):519-28. PubMed ID: 8395457
    [Abstract] [Full Text] [Related]

  • 19. [ANP in the cirrhotic patient. A clinical contribution].
    Parlapiano C, Labellarte A, Primi F, Cervellini P, La Torre F, Paparo SB, Baccarini S, Di Nardo A.
    Minerva Endocrinol; 1994 Sep 19; 19(3):121-6. PubMed ID: 7799893
    [Abstract] [Full Text] [Related]

  • 20. [Pathogenesis of ascites formation in liver cirrhosis (author's transl)].
    Arbeiter G, Meyer-Burg J.
    Leber Magen Darm; 1974 Oct 19; 4(6):299-307. PubMed ID: 4373632
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.